Mice NNP I-NP I-T
bearing VBG I-NP I-T
the DT B-NP I-T
orthotopic NN I-NP I-T
model NN I-NP I-T
were VBD I-VP O
treated VBN I-VP O
starting VBG I-VP O
from IN I-PP O
day NN I-NP O
21 CD I-NP O
after IN I-PP O
NB NNP I-NP O
cell NN I-NP O
implant; NN I-NP O
mice NN I-NP I-T
with IN I-PP I-T
the DT I-NP I-T
pseudo-metastatic JJ I-NP I-T
model NN I-NP I-T
received VBD I-VP O
the DT I-NP O
first JJ I-NP O
treatment NN I-NP O
4h CD I-NP O
after IN I-PP O
NB NNP I-NP O
cell NN I-NP O
injection. NN I-NP O

These DT I-NP I-T
therapeutic JJ I-NP I-T
schedules NNS I-NP I-T
were VBD I-VP O
designed VBN I-VP O
to TO I-VP O
test VB I-VP I-P
the DT I-NP I-P
effects NNS I-NP I-P
of IN I-PP O
our PRP$ I-NP I-M
targeted JJ I-NP I-M
formulations NNS I-NP I-M
against IN I-PP O
both DT I-NP O
established VBN I-NP O
and CC O O
pseudo-metastatic JJ I-NP O
preclinical JJ I-NP I-M
models NNS I-NP I-M
of IN I-PP O
human JJ I-NP O
NB, NNP I-NP O
as IN I-PP O
described VBN I-NP O
[16,19]. NN I-NP O

Animals NNS I-NP I-T
were VBD I-VP O
treated VBN I-VP O
i.v. NN I-NP O

once RB O O
a DT I-NP O
week NN I-NP O
for IN I-PP O
3 CD I-NP O
weeks NNS I-NP O
with IN I-PP O
untargeted JJ I-NP I-M
(SL[DXR]) NN I-NP O
or CC O O
peptide-targeted JJ I-NP I-M
SL[DXR] NNP I-NP I-M
(5mg/kg). NN I-NP O

Scrambled VBN I-VP I-T
peptide-functionalized JJ I-NP I-T
liposomes NNS I-NP I-T
were VBD I-VP O
used VBN I-VP O
as IN I-PP O
a DT I-NP O
control, NN I-NP O
and CC O O
in IN I-PP O
every DT I-NP O
experiment NN I-NP O
a DT B-NP O
group NN I-NP O
of IN I-PP O
control NN I-NP O
mice NN I-NP O
received VBD I-VP O
HEPES-buffered NNP I-NP I-M
saline. NN I-NP I-M

Survival JJ I-NP I-M
times NNS I-NP I-M
were VBD I-VP O
used VBN I-VP O
as IN I-PP O
the DT I-NP O
main JJ I-NP O
criterion NN I-NP O
for IN I-PP O
determining VBG I-VP I-T
treatment NN I-NP I-T
efficacy. NN I-NP I-T

In IN I-PP O
the DT I-NP O
orthotopic NN I-NP I-T
model, VBD I-VP I-T
time-dependent JJ I-NP I-M
anti-tumor JJ I-NP I-M
activity NN I-NP I-M
was VBD I-VP O
also RB I-VP O
evaluated VBN I-VP O
by IN I-PP O
bioluminescence NN I-NP O
imaging VBG I-NP O
(BLI) JJ I-NP O
and CC O O
X-ray JJ I-NP O
analyses. NN I-NP O

For IN I-PP O
this DT I-NP O
purpose, VBZ I-VP O
the DT I-NP I-T
GI-LI-N NNP I-NP I-T
cell NN I-NP I-T
line NN I-NP I-T
was VBD I-VP O
infected VBN I-VP I-P
with IN I-PP O
a DT I-NP O
retrovirus NN I-NP O
expressing VBG I-VP O
the DT I-NP O
firefly NN I-NP O
luciferase NN I-NP O
gene, NN I-NP O
as IN I-PP O
previously RB I-NP O
reported VBN I-NP O
[17]; JJ I-NP O
luciferase NN I-NP I-T
activity NN I-NP I-T
of IN I-PP O
retrovirally-transduced JJ I-NP I-M
cells NNS I-NP I-M
was VBD I-VP O
visualized VBN I-VP I-P
in IN I-PP O
vivo NN I-NP O
by IN I-PP O
BLI NNP I-NP O
(IVIS NNP I-NP O
Caliper NNP I-NP O
Life NNP I-NP O
Sciences, NNP I-NP O
Hopkinton, NNP I-NP O
MA) NNP I-NP O
after IN I-PP O
a DT I-NP O
10min CD I-NP O
incubation NN I-NP O
with IN I-PP O
150Î¼g/mL CD I-NP O
of IN I-PP O
d-luciferin JJ I-NP I-M
(Caliper NNP I-NP O
Life NNP I-NP O
Sciences), NNP I-NP O
as IN I-PP O
described VBN I-NP O
[17]. NN I-NP O

X-ray JJ I-NP O
analysis NN I-NP O
was VBD I-VP O
superimposed VBN I-VP O
to TO I-VP O
the DT I-NP O
luminescence NN I-NP O
for IN I-PP O
a DT I-NP O
better JJR I-NP O
visualization NN I-NP O
of IN I-PP O
the DT I-NP O
tumors. NN I-NP O

